Meta-Analysis
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jan 15, 2021; 12(1): 84-97
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.84
Novel glucose-lowering drugs for non-alcoholic fatty liver disease
Zuo-Di Fu, Xiao-Ling Cai, Wen-Jia Yang, Ming-Ming Zhao, Ran Li, Yu-Feng Li
Zuo-Di Fu, Department of Endocrinology, Beijing Friendship Hospital Pinggu Campus, Beijing 101200, China
Xiao-Ling Cai, Wen-Jia Yang, Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing 100044, China
Ming-Ming Zhao, The Institute of Cardiovascular Sciences, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing 100079, China
Ran Li, Sport Science School, Beijing Sport University, Beijing 100078, China
Yu-Feng Li, Department of Endocrinology, Beijing Friendship Hospital Pinggu Campus, Capital Medical University, Beijing 101200, China
Author contributions: Li YF, Zhao MM, and Li R conceived and designed the review; Fu ZD, Cai XL, and Yang WJ provided statistical analysis and drafted the manuscript. All authors read and approved the final manuscript.
Supported by The Capital's Funds for Health Improvement and Research, No. CFH2020-2-7131.
Conflict-of-interest statement: We declare no competing interests.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Feng Li, MD, Chief Doctor, Department of Endocrinology, Beijing Friendship Hospital Pinggu Campus, Captital Medical University, No. 59 North Xinping Road, Beijing 101200, China. yflee@bjmu.edu.cn
Received: September 21, 2020
Peer-review started: September 21, 2020
First decision: November 16, 2020
Revised: November 22, 2020
Accepted: December 2, 2020
Article in press: December 2, 2020
Published online: January 15, 2021
Core Tip

Core Tip: The efficacy of novel glucose-lowering drugs in treating non-alcoholic fatty liver disease is unknown. The results of this meta-analysis showed that treatment with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors resulted in improvements in serum alanine aminotransferase and aspartate aminotransferase levels, indicating a beneficial effect in the improvement of liver injury.